Jump to content

BB Biotech: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Valere-ab (talk | contribs)
62 edits
independent company connected to Bellevue Group (not BB Biotech)
m Sentence restructuring.
Line 19: Line 19:
}}
}}


'''BB Biotech AG''' is a [[Switzerland|Swiss]] [[investment company]] in the field of [[biotechnology]]. Since 1993 it is listed on the [[SIX Swiss Exchange]], since 1997 on the German [[TecDAX]] and from 2000 to 2023<ref>{{Cite web |date=2023-08-21 |title=Delisting from Borsa Italiana |url=https://www.bbbiotech.ch/ch-en/private/investors/corporate-news/delisting-from-borsa-italiana |access-date=2023-08-31 |website=BB Biotech}}</ref> on the Italian [[Borsa Italiana]].<ref>{{cite web|url=https://www.borsaitaliana.it/borsa/azioni/scheda/CH0038389992.html?lang=en|title=BB Biotech |publisher=Borsa Italiana|accessdate=3 June 2020}}</ref> The company invests mainly in the United States and Western Europe.<ref name="A">{{cite web |url=https://www.bloomberg.com/quote/BB:IM |title=BB Biotech AG |publisher=Bloomberg |access-date=8 January 2022}}</ref> BB Biotech is managed by Bellevue Asset Management, a division of Bellevue Group<ref name="M_210211">{{cite web |author1=QuotedData by Marten & Co |title=BB Biotech AG. A leading biotech investor |url=https://quoteddata.com/wp-content/uploads/2021/02/210211-BION-Initiation-IN.pdf |access-date=7 November 2021 |date=11 February 2021}}</ref> and accounts for approximately 40% of the Group's [[assets under management]].<ref name="quoteddata">{{cite web |title=BB Biotech AG - A leading biotech investor |url=https://quoteddata.com/research/bb-biotech-ag-leading-biotech-investor-in/ |website=QuotedData |access-date=7 November 2021 |language=en |date=11 February 2021}}</ref>
'''BB Biotech AG''' is a [[Switzerland|Swiss]] [[investment company]] in the field of [[biotechnology]]. Since 1993 it is listed on the [[SIX Swiss Exchange]], since 1997 on the German [[TecDAX]] and from 2000 to 2023<ref>{{Cite web |date=2023-08-21 |title=Delisting from Borsa Italiana |url=https://www.bbbiotech.ch/ch-en/private/investors/corporate-news/delisting-from-borsa-italiana |access-date=2023-08-31 |website=BB Biotech}}</ref> on the Italian [[Borsa Italiana]].<ref>{{cite web|url=https://www.borsaitaliana.it/borsa/azioni/scheda/CH0038389992.html?lang=en|title=BB Biotech |publisher=Borsa Italiana|accessdate=3 June 2020}}</ref> The company invests mainly in the United States and Western Europe<ref name="A">{{cite web |url=https://www.bloomberg.com/quote/BB:IM |title=BB Biotech AG |publisher=Bloomberg |access-date=8 January 2022}}</ref> and is managed by Bellevue Asset Management, a division of Bellevue Group<ref name="M_210211">{{cite web |author1=QuotedData by Marten & Co |title=BB Biotech AG. A leading biotech investor |url=https://quoteddata.com/wp-content/uploads/2021/02/210211-BION-Initiation-IN.pdf |access-date=7 November 2021 |date=11 February 2021}}</ref> which accounts for approximately 40% of the Group's [[assets under management]].<ref name="quoteddata">{{cite web |title=BB Biotech AG - A leading biotech investor |url=https://quoteddata.com/research/bb-biotech-ag-leading-biotech-investor-in/ |website=QuotedData |access-date=7 November 2021 |language=en |date=11 February 2021}}</ref>


==Investment activities==
==Investment activities==

Revision as of 16:17, 24 October 2023

BB Biotech AG
Company typeAktiengesellschaft
SIX: BION[1]
FWB: BBZA[2]
Euronext: BIO.MI[3]
IndustryInvestments
Founded9 November 1993 (9 November 1993)[4]
HeadquartersSchaffhausen, Switzerland[5]
Key people
Erich Hunziker
(Chairman)[6]
ProductsInvestment in biotechnology companies
Increase CHF - 357 million
(2022)[7]
Total assetsDecreaseCHF 2.578 billion
(2022)[7]
Websitewww.bbbiotech.ch

BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and from 2000 to 2023[8] on the Italian Borsa Italiana.[9] The company invests mainly in the United States and Western Europe[10] and is managed by Bellevue Asset Management, a division of Bellevue Group[11] which accounts for approximately 40% of the Group's assets under management.[12]

Investment activities

As a closed-end fund, with its principal activity of specialised investments in companies operating in biotech sector,[13][14] BB Biotech is the oldest-established[12] and largest entity of its kind.[11][15]

BB Biotech's investment strategy covers a long-term time horizon and targets biotechnology firms with either already established products in the marketplace[16] or promising drug candidates in advanced development stages.[17]

Aiming exclusively at human therapeutic companies, the company rules out med-tech, diagnostics and other similar activities[12] and further concentrates on firms developing therapeutic products[13] involving cell, gene and particularly RNA-based technologies.[12]

In contrast to other biotech specialists or hedge funds, Biotech as a long-only investor, does not need to rely on financial instruments to reduce individual stock or market risk.[12]

Primary geographic focus lies on small-to-mid-cap biotech companies headquartered in Western Europe[18] or the United States market[19] as a domicile for the majority of the world’s biotechnology companies,[20] or those listed on Nasdaq.[12]

While benchmarked against the Nasdaq Biotech index (in CHF),[21][22] the company uses a bottom-up approach[17] based on the fundamental analysis.[12] Its portfolio comprises around 35 companies[14] and includes holdings in Ionis Pharmaceuticals, Moderna, Neurocrine Biosciences, Argenx, Incyte, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Arvinas, Fate Therapeutics, Agios Pharmaceuticals and Halozyme Therapeutics.[23]

Over the decade leading to 2020, it consistently met its own aim to deliver 15% of annual growth in capital[12] including a 5% dividend per year.[11]

History

BB Biotech AG mainly invests in the fields of oncology, cardiovascular diseases, metabolic diseases, infectious diseases and autoimmune diseases.[14]

Core investments

The six core investments in the BB Biotech portfolio as of June 30, 2023 included Ionis Pharmaceuticals (13.3%), Argenx (11.7%), Vertex (10.4%), Neurocrine Biosciences (8.5%), Intra-Cellular Therapies  (6.9%) and Moderna (6.2%).[24]

Company figures

Company figures are as follows:[25][26]

(figures in millions CHF) 2022 2021 2020 2019 2018 2017 2016 2015
Profit/(Loss) (356)[27] (405) 691[7][28] 677 (471) 687 (802) 653
Net asset value 2'686 3'283 3'888[28] 3'393 2'885 3'539 3'003 3'978
Market capitalization 3'058 4’274 4108[29][28] 3'670 3'235 3'576 3'053 3'463

References

  1. ^ "BION.S - BB BIOTECH AG All Listings | Reuters". www.reuters.comundefined. Retrieved 20 October 2021.
  2. ^ "BB Biotech AG Equity | A0NFN3 | CH0038389992 | Share Price". www.boerse-frankfurt.de. Retrieved 20 October 2021.
  3. ^ "Bb Biotech Stocks Quotes: Company Profile - Borsa Italiana". www.borsaitaliana.it. Retrieved 20 October 2021.
  4. ^ AG, DV Bern. "BB Biotech AG". Official Companies Register of the Canton of Schaffhausen (in German). Retrieved 20 October 2021.
  5. ^ "BB Biotech AG. Zentraler Firmenindex". www.zefix.ch (in German). Retrieved 20 October 2021.
  6. ^ "BB BIOTECH - About us. Board of Directors". www.bbbiotech.ch. Retrieved 20 October 2021.
  7. ^ a b c "BB Biotech AG, BION:SWX financials - FT.com". markets.ft.com. Retrieved 31 August 2023.
  8. ^ "Delisting from Borsa Italiana". BB Biotech. 2023-08-21. Retrieved 2023-08-31.
  9. ^ "BB Biotech". Borsa Italiana. Retrieved 3 June 2020.
  10. ^ "BB Biotech AG". Bloomberg. Retrieved 8 January 2022.
  11. ^ a b c QuotedData by Marten & Co (11 February 2021). "BB Biotech AG. A leading biotech investor" (PDF). Retrieved 7 November 2021.
  12. ^ a b c d e f g h "BB Biotech AG - A leading biotech investor". QuotedData. 11 February 2021. Retrieved 7 November 2021.
  13. ^ a b "BB Analysis - BB Biotech AG Fund - Bloomberg Markets". www.bloomberg.com. Bloomberg. Retrieved 8 January 2022.
  14. ^ a b c "BB Biotech AG 0JYO-GB:London Stock Exchange". CNBC. Retrieved 2 June 2022.
  15. ^ "BB Biotech AG Share Price | BIOEE | Morningstar". Retrieved 2 June 2022.
  16. ^ "BB Biotech AG Bearer Shares (BBAGF)". NASDAQ, Inc. Retrieved 2 June 2022.
  17. ^ a b Sarah Godfrey, Mel Jenner. "BB Biotech SW: BION". Edison Investment Research Limited. Retrieved 2 June 2022.
  18. ^ "DGAP-News: BB BIOTECH AG: Disruptive technologies are changing an entire industry". www.finanzen.ch. 24 May 2022. Retrieved 2 June 2022.
  19. ^ "BB Biotech AG, BION:SWX profile - FT.com". markets.ft.com. Retrieved 7 November 2021.
  20. ^ Sarah Godfrey, Mel Jenner (1 March 2021). "BB Biotech - Looking for innovation beyond the pandemic. Review". Edison Investment Research Limited. Retrieved 2 June 2022.
  21. ^ Kadhim Shubber (24 August 2015). "US biotech tumbles into bear market". Financial Times. Retrieved 2 June 2022.
  22. ^ Evans, Richard (9 December 2021). "Questor: biotech has been shunned this year despite the vaccines triumph – so buy these trusts". The Telegraph. Retrieved 2 June 2022.
  23. ^ "BB Biotech - Our holdings". www.bbbiotech.ch. BB Biotech AG. Retrieved 8 January 2022.
  24. ^ "Portfolio". BB Biotech. Retrieved 2023-08-31.
  25. ^ finanzen.net Retrieved 1st of January 2016.
  26. ^ "BB Biotech - Facts & Figures". BB Biotech. 11 March 2020. Archived from the original on 2016-03-21.
  27. ^ "Annual Report 2022". BB Biotech. Retrieved 2023-08-31.
  28. ^ a b c "BB BIOTECH -Facts & Figures". www.bbbiotech.ch. Retrieved 20 October 2021.
  29. ^ "BB Biotech - Annual Report 2020". BB Biotech - Annual Report 2020. Retrieved 20 October 2021.
Stub icon

This Swiss corporation or company article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=BB_Biotech&oldid=1181686084"